Current Oncology Reports

, Volume 4, Issue 4, pp 341–346

Chemoprevention of lung cancer

  • Edward S. Kim
  • Fadlo R. Khuri
Article

Abstract

Lung cancer is the leading cause of death worldwide. Its overall survival rate has improved only slightly, and surgery, radiotherapy, and chemotherapy remain the mainstays of current treatment. Therapies with novel targeted agents are currently under active investigation in all settings of treatment including chemoprevention, defined as the use of natural or synthetic agents to interrupt the process of carcinogenesis and to prevent or delay tumor occurrence. Thus, chemoprevention describes the collaborative efforts of researchers in basic science and clinical settings who study the biology of lung cancer with the hope of uncovering new mechanisms of treatment. Because lung cancer has become an increasingly difficult problem to treat with standard therapies, chemopreventive strategies have been developed. Small molecule compounds that target specific receptors or mutations will play an increasingly significant role in treatment of lung cancer because the side effect profiles of such agents are tolerable and they may be more effective than other treatments.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jemal A, Thomas A, Murray T, et al.: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Adler I: Primary Malignant Growths of the Lung and Bronchi. New York: Longmans, Green; 1912.Google Scholar
  3. 3.
    Ochsner A, Debakey M: Carcinoma of the lung. Arch Surgery 1940, Dec:209–258.Google Scholar
  4. 4.
    Auerbach O, Gere JB, Forman JB, et al.: Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1957, 256:98–104.CrossRefGoogle Scholar
  5. 5.
    Auerbach O, Hammond EC, Garfinkel L: Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs. 1970–1977. N Engl J Med 1979, 300:381–386.PubMedCrossRefGoogle Scholar
  6. 6.
    Auerbach O, Stout AP, Hammond EC, et al.: Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961, 265:253–267.PubMedCrossRefGoogle Scholar
  7. 7.
    Arnold AM, Browman GP, Levine MN, et al.: The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992, 65:737–743.PubMedGoogle Scholar
  8. 8.
    Gouveia J, Hercend T, Lemaigre G, et al.: Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1982, 1:710–712.PubMedCrossRefGoogle Scholar
  9. 9.
    Lee JS, Lippman SM, Benner SE, et al.: A randomized placebocontrolled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994, 12:937–945.PubMedGoogle Scholar
  10. 10.
    Mathe G, Gouveia J, Hercend R, et al.: Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment. Cancer Detect Prev 1982, 5:461–466.PubMedGoogle Scholar
  11. 11.
    Misset JL, Santelli G, Homasson JP, et al.: Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev 1986, 9:167–170.PubMedGoogle Scholar
  12. 12.
    Heimberger DC, Alexander CB, Birch R, et al.: Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: report of a preliminary randomized double-blind intervention trial. JAMA 1988, 259:1525–1530.CrossRefGoogle Scholar
  13. 13.
    Hong WK, Endicott J, Itri LM, et al.: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315:1501–1505.PubMedCrossRefGoogle Scholar
  14. 14.
    Lippman SM, Batsakis JG, Toth BB, et al.: Comparison of lowdose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993, 328:15–20.PubMedCrossRefGoogle Scholar
  15. 15.
    The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of Vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029–1035.CrossRefGoogle Scholar
  16. 16.
    Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Decker J, Goldstein JC: Risk factors in head and neck cancer. N Engl J Med 1982, 306:1151–1155.PubMedCrossRefGoogle Scholar
  18. 18.
    Hennekans CH, Buring JE, Manson JE, et al.: Lack of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145–1149.CrossRefGoogle Scholar
  19. 19.
    Goodman M, Morgan RW, Ray R, et al.: Cancer in asbestosexposed occupational cohorts: a meta-analysis. Cancer Causes Control 1999, 10:453–465.PubMedCrossRefGoogle Scholar
  20. 20.
    Wynder EL, Stellman SD: Impact of long-term filter cigarette usage on lung and larynx cancer risk: a case-control study. J Natl Cancer Inst 1979, 62:471–477.PubMedGoogle Scholar
  21. 21.
    Boice JD, Fraumeni JF: Second cancer following cancer of the respiratory system in Connecticut, 1935–1982. Natl Cancer Inst Monogr 1985, 68:83–98.PubMedGoogle Scholar
  22. 22.
    Gluckman JL, Crissman JD: Survival rates in 548 patients with multiple neoplasms of the upper aerodigestive tract. Laryngoscope 1983, 93:71–74.PubMedGoogle Scholar
  23. 23.
    De Vries N, Snow GB: Multiple primary tumours in laryngeal cancer. J Laryngol Otol 1986, 100:915–918.PubMedGoogle Scholar
  24. 24.
    Yellin A, Hill LR, Benfield JR: Bronchogenic carcinoma associated with upper aerodigestive cancers. J Thoracic Cardiovasc Surg 1986, 91:674–683.Google Scholar
  25. 25.
    Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer. N Engl J Med 1993, 328:184–193.PubMedCrossRefGoogle Scholar
  26. 26.
    Lippman SM, Hong WK: Not yet standard: retinoids versus second primary tumors. J Clin Oncol 1993, 11:1204–1207.PubMedGoogle Scholar
  27. 27.
    Lippman SM, Hong WK: Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early stage disease. Int J Radiat Oncol Biol Phys 1989, 17:691–694.PubMedGoogle Scholar
  28. 28.
    Larson JT, Adams GL, Fattah HA: Survival statistics for multiple primaries in head and neck cancer. Otolaryngol Head Neck Surg 1990, 103:14–24.PubMedGoogle Scholar
  29. 29.
    Tepperman BS, Fitzpatrick PJ: Second respiratory and upper digestive tract cancers after oral cancer. Lancet 1981, 9:547–549.CrossRefGoogle Scholar
  30. 30.
    Vikram B: Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 1984, 110:564–565.PubMedGoogle Scholar
  31. 31.
    Licciardello JT, Spitz MR, Hong WK: Multiple primary cancers in patients with cancer of the head and neck: second cancer of the head and neck, esophagus and lung. Int J Radiat Oncol Biol Phys 1989, 17:467–476.PubMedGoogle Scholar
  32. 32.
    McDonald S, Haie C, Rubin P, et al.: Second malignant tumors in patients with laryngeal carcinoma: diagnosis, treatment and prevention. Int J Radiat Oncol Biol Phys 1989, 17:457–465.PubMedGoogle Scholar
  33. 33.
    Warren S, Gates O: Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932, 16:1358–1403.Google Scholar
  34. 34.
    Hong WK, Lippman SM, Itri LM, et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990, 323:795–801.PubMedCrossRefGoogle Scholar
  35. 35.
    Benner SE, Lippman SM, Hong WK: Current status of chemoprevention of head and neck cancer. Oncology 1992, 6:61–66.PubMedGoogle Scholar
  36. 36.
    Benner SE, Pajak TF, Stetz J, et al.: Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer. J Natl Cancer Inst 1994, 86:1799–1801.PubMedCrossRefGoogle Scholar
  37. 37.
    Khuri FR, Lee JJ, Winn RJ, et al.: Interim analysis of randomized chemoprevention trial of HNSCC [abstract]. Proc ASCO 1999, 18:1503.Google Scholar
  38. 38.
    Kim ES, Khuri FR, Lee JJ, et al.: Second primary tumor incidence related to primary index tumor and smoking status in a randomized chemoprevention study of head and neck squamous cell cancer [abstract]. Proc ASCO 2000, 19:1642.Google Scholar
  39. 39.
    de Vries N, van Zandwijk N, Pastorino U: Chemoprevention of head and neck and lung (pre)cancer. Recent Results Cancer Res 1999, 151:13–25.PubMedGoogle Scholar
  40. 40.
    Khuri FR, Kim ES, Lee JJ, et al.: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the Head and Neck Retinoid Chemoprevention Trial. Cancer Epidemiol Biomarkers Prev 2001, 10:823–829. This report from the Head and Neck Retinoid Chemoprevention Second Primary Tumor Trial reflects the first large-scale chemoprevention study evaluating smoking status and its impact on the development of SPTs.PubMedGoogle Scholar
  41. 41.
    van Zandwijk N, Dalesio O, Pastorino U, et al.: EUROSCAN: a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000, 92:977–986. Another trial that did not show significant activity of chemoprevention agents in patients with lung or head and neck cancer.PubMedCrossRefGoogle Scholar
  42. 42.
    Lippman SM, Lee JJ, Karp DD, et al.: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 2001, 93:605–618. This trial demonstrated no beneficial effect of isotretinoin in patients with early-stage lung cancer.PubMedCrossRefGoogle Scholar
  43. 43.
    Mayne ST, Cartmel B, Baum M, et al.: Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 2001, 61:1457–1463. This trial showed no benefit of beta-carotene in the prevention of second primary tumors of the head, neck, and lung.PubMedGoogle Scholar
  44. 44.
    Shin DM, Khuri FR, Murphy B, et al.: Combined interferonalfa, 13 cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001, 19:3010–3017. This trial demonstrated that biochemoprevention is a feasible and effective approach for locally advanced disease.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2002

Authors and Affiliations

  • Edward S. Kim
    • 1
  • Fadlo R. Khuri
    • 1
  1. 1.Department of Thoracic/Head and Neck Medical OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations